ClinicalTrials.gg
RecruitingNCT05603910Updated Nov 18, 2026

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

A Phase 1 interventional study of Lenvatinib and Pembrolizumab in Recurrent Endometrial Carcinoma and Unresectable Endometrial Carcinoma, sponsored by Aaron Wolfson. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Aaron Wolfson · Phase 1, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.
Updated Nov 18, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing lenvatinib in Endometrial Neoplasms — 4 open to participants now, 6 under way, none of them phase 3. lenvatinib · Endometrial Neoplasms.

Planned enrollment
12th of 15
18 · median 32
Started
2023
with 1 other
Phase 1
3 of 15
1 open now
Registered
11th of 15
by date
Lead sponsor
1 of 15
Aaron Wolfson

Among the 15 studies testing lenvatinib in Endometrial Neoplasms, this one is the 12th largest by planned enrollment, is one of 2 that started in 2023, is one of 3 in phase 1, and was the 11th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

4 of the 15 studies testing lenvatinib in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing lenvatinib in Endometrial Neoplasms, or all of them as a file.
02

Study summary

The purpose of this research study is to see if it is feasible to combine a fixed dose of pembrolizumab and a daily dose of oral lenvatinib, along with daily treatments of an abbreviated course of pelvic external beam radiation therapy, to support cancer cells in multiplying and spreading to other body sites.

03

Conditions studied

  • Recurrent Endometrial Carcinoma
  • Unresectable Endometrial Carcinoma
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. -proven recurrent pMMR EC following surgery alone or de novo unresectable pMMR EC for whom EBRT has been determined as an appropriate therapeutic approach. Eligible tumor histologies include the following: endometrioid adenocarcinoma, adenocarcinoma with squamous differentiation, mucinous, mixed carcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, serous adenocarcinoma, and uterine carcinosarcoma histologies as determined by tissue from an archival sample or newly obtained core or excisional biopsy of a tumor lesion. For patients with recurrent disease greater than 12 months (>12 months), a fresh biopsy must be obtained.
  • 2. of at least 1.0 cm in size defined by 1.1 on imaging studies with at least one (1) site located in the pelvis and/or vagina without any foci of extra-pelvic disease (including the para-aortic region or inguinal-femoral lymph nodes).
  • 3. Patients must have (ECOG) performance status of 0-2 ( score ≥50).
  • 4. Patients must have pMMR tumor subtype(s).
  • 5. Patients must have normal organ and marrow function as defined below:

    • a. (ANC) ≥1,000 cells/mm³
    • b. ≥100,000 cells/mm³
    • c. ≥9.0 g/dL
    • d. Creatine clearance () ≥ 30 mL/min or Measured or calculated a creatinine clearance (GFR) can also be used in place of creatinine. CrCl should be calculated per institutional standard.
    • e. Serum total \<1.0
    • f. (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine transaminase (ALT) serum glutamic-pyruvic transaminase (SGPT) Aminotransferase (AST and ALT) ≤ 2.5 x ULN or 5 X ULN for patients with liver
    • g. Albumin ≥2.5 mg/dL
  • 6. Female participants of (those who have not been surgically sterilized or have not been without menses for >1 year) should be willing to use 2 methods of at the same time or be surgically sterile or abstain from heterosexual activity for the course of the study and for at least 120 days after the last study dose.
  • 7. Ability to understand and the willingness to sign a written document.
  • 8. Prior treatment with lenvatinib, anti-programmed cell death protein 1 (), anti-Programmed death-ligand 1 (anti-PD-L1) , or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways is allowed provided that the participant has not received any of these treatments within three weeks (+/- 3 days) of the first dose of study treatment.
  • 9. Women age ≥18 years old.
  • 10. Patients who have received prior adjuvant vaginal high dose rate (HDR) brachytherapy without EBRT following hysterectomy will be eligible as long as the cumulative Equivalent Dose at 2-Gy (EqD2) for external beam pelvic dose and vaginal HDR brachytherapy dose for the rectum and sigmoid colon is at most 70 Gy, for bowel at most 65 Gy, and for bladder at most 90 Gy.

Exclusion criteria

Exclusion Criteria:

  • 1. Patients who are currently in or have participated in a study of an agent or used an investigational device within 4 weeks of the first dose of study treatment.
  • 2. Patients with Mismatch repair deficient (dMMR) and endometrial carcinomas.
  • 3. Patients with dMMR and uterine carcinosarcomas.
  • 4. Patients with known active central nervous system (CNS) and/or carcinomatous meningitis.

EXCEPTION: Patients with previously treated , including receiving prior brain irradiation, may participate provided they are stable (without evidence of progression by imaging for at least 3 months prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, are not using for at least 28 days prior to study treatment, and have not received prior cranial irradiation for at least 3 months prior to study treatment.

  • 5. Patients with a known additional that is progressing or requires active treatment. EXCEPTIONS include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
  • 6. No prior external beam radiation therapy to the vagina, pelvis, and/or abdomen will be allowed.
  • 7. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or other serious medical condition or social situations that in the judgement of the Investigator(s) would interfere or limit compliance with study requirements/treatments.
  • 8. Receiving systemic steroid therapy or any other form of therapy within 21 days prior to the first dose of study treatment. Note: Patients with active disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids or immunosuppressive drugs) and/or requiring replacement therapy (i.e., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • 9. Evidence of interstitial lung disease or active, non-infectious pneumonitis.
  • 10. Evidence of uncontrolled hypertension as documented in the patient's medical record.
  • 11. Known psychiatric illness/condition or substance abuse disorders that in the judgement of the Investigator(s) would interfere with cooperation with requirements of the study.
  • 12. Is pregnant or breastfeeding or expecting to conceive within the projected duration of the study, starting with the pre-screening or screening visit through - 120 days after the last dose of study treatment.
  • 13. Patients with uncontrolled (HIV) infection, which is defined as follows:

    • a. Antiviral therapy treatment for \<4 weeks AND
    • b. Have an HIV viral load ≥400 copies/mL prior to enrollment.
  • 14. Patients with uncontrolled virus (HBV) infection or who are chronic carriers of hepatitis B infection, which is defined as:

    • a. Hepatitis B surface antigen reactive (HbsAg-positive), undetectable or low HBV DNA, and with normal levels who are not on HBV therapy
    • b. Individuals who have serologic evidence of a resolved prior HBV infection (ie, HBSAg-negative and anti-core hepatitis B antibody positive (anti-Hepatitis B core -positive)
  • 15. Patients with active, untreated virus (HCV) infection or who have not completed their HCV antiviral regimen. Patients with a history of HCV infection may participate in this study if their HCV ribonucleic acid (RNA) level is below the limit of quantification.
  • 16. Received within 30 days prior to the first dose of study treatment.
  • 17. Patient has active Mycobacterium tuberculosis infection (tuberculosis or TB).
  • 18. A corrected for heart rate using Bazett's formula (QTcB) ≥ 480msec.
  • 19. Patient receiving concurrent additional biologic therapy.
  • 20. Patients with impaired decision-making capacity.
  • 21. Patients who have not recovered from major surgery.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Lenvatinib, Pembrolizumab and Hypofractionated (HypoFx) External Beam Radiation Therapy (EBRT) Group

    Participants in this group will receive a combination treatment of Lenvatinib, Pembrolizumab, and HypoFx Pelvic EBRT over a period of approximately 10 to 12 weeks: * Lenvatinib self-administered daily starting on Day 1 of the study treatment period and continuing until the last dose of whole pelvic HypoFx EBRT is received. * Pembrolizumab administered on Day 1, 22 and 43. * Whole pelvic HypoFx EBRT beginning on Day 22. After receiving whole pelvic Hypo EBRT, participants will receive a boost course of radiation therapy using one of the following techniques: * Pelvic boost HypoFx EBRT to be administered over a period of 1.5 to 2 weeks; OR * Vaginal HDR brachytherapy boost to be administered over a period of 2 to 3 weeks, depending on the lesion thickness; OR * Both pelvic boost HypoFx EBRT pelvic plus vaginal HDR brachytherapy boost. The overall radiation therapy treatment time for whole pelvic HypoFx RT and radiation boost treatments is approximately 7 weeks.

    Drug: Lenvatinib · Drug: Pembrolizumab · Radiation: Hypofractionated External Beam Radiation Therapy · Radiation: High-Dose Rate (HDR) Brachytherapy

Interventions

  • Lenvatinib will be self-administered orally (PO) by participants in a 3+3 escalation/de-escalation design. Participants will receive one of the following four dose levels: * Dose level 1: 4 mg * Dose level 2: 8 mg * Dose level 3: 12 mg (Starting dose) * Dose level 4: 16 mg

    Also known as: Lenvima

  • Pembrolizumab 200 mg will be administered intravenously (IV) once on Days 1, 22 and 43.

    Also known as: Keytruda

  • RadiationHypofractionated External Beam Radiation Therapy

    Whole pelvic HypoFx EBRT consisting of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 17.5 Gy, delivered to site(s) of gross disease of at least 1.0 cm in size.

  • RadiationHigh-Dose Rate (HDR) Brachytherapy

    Vaginal high-dose rate (HDR) brachytherapy administered per standard of care (SoC) techniques.

06

What researchers measure

Primary outcomes

  1. Recommended Phase 2 Dose (RP2D) of Lenvatinib

    The RP2D will be the highest dose of Lenvatinib that in combination with Pembrolizumab and Hypofractionated (HypoFx) pelvic External Beam Radiotherapy (EBRT) yields less than 2 Dose Limiting Toxicities (DLTs) in 6 patients.

    Time frame: Up to 12 weeks

  2. Number of Participants Experiencing Treatment-Related Toxicity: Dose-Limiting Toxicities (DLTs)

    The number of participants experiencing treatment-related DLTs will be reported. DLTs will be assessed by the treating physician using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

    Time frame: Up to 12 weeks

  3. Number of Participants Experiencing Treatment-Related Toxicity: Adverse Events (AEs)

    The number of participants experiencing treatment-related adverse events (AEs) will be reported. AEs will be assessed by the treating physician using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the number of participants achieving a Complete Response (CR) or Partial Response (PR) to study therapy according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

    Time frame: Up to 12 weeks

  2. Number of Participants Experiencing Non-Treatment-Related Adverse Events

    The number of participants experiencing non-treatment-related adverse events (AEs) will reported. AEs will be assessed by the treating physician using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

    Time frame: Up to 12 weeks

07

Study locations

1 of 1 sites recruiting
  • University of Miami
    Miami, Florida 33136, United States
    Recruiting
    • Aaron H Wolfson, MD, FACR · Contactawolfson@med.miami.edu · 954-698-3680
    • Aaron H Wolfson, MD, FACR · Principal investigator
    • Matthew Sclhumbrecht, MD, MPH · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Apr 2029, 72 months after the start.

Of 43 non-industry phase 1 interventional studies under Endometrial Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 80. This study's planned 72 months is close to that.

Counting every sponsor, half of 131 studies reached it within 61 months; a quarter within 46 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2022
First posted
Nov 3, 2022
StartActual
Apr 15, 2023
Primary completionEst.
Apr 15, 2029
CompletionEst.
Apr 15, 2034
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
3 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Editeda. Absolute neutrophil count (ANC) ≥1,500000 cells/mm³
  • EditedSerum creatinine ≤ 1.5 x upper limit of normal (ULN) or creatined. Creatine clearance (CrCl) ≥ 4030 mL/min or Measured or calculated a creatinine clearance glomerular filtration rate (GFR) can also be used in place of creatinine. CrCl should be calculated per institutional standard.
  • Editedg. Albumin ≥2.5 mg/dL CrCl should be calculated per institutional standard.
Exclusion criteria
  • Edited12. Is pregnant or breastfeeding or expecting to conceive within the projected duration of the study, starting with the pre-screening or screening visit through - 120 days after the last dose of study treatment.
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Eligibility 3 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Editeda. Absolute neutrophil count (ANC) ≥1,500000 cells/mm³
    • EditedSerum creatinine ≤ 1.5 x upper limit of normal (ULN) or creatined. Creatine clearance (CrCl) ≥ 4030 mL/min or Measured or calculated a creatinine clearance glomerular filtration rate (GFR) can also be used in place of creatinine. CrCl should be calculated per institutional standard.
    • Editedg. Albumin ≥2.5 mg/dL CrCl should be calculated per institutional standard.
    Exclusion criteria
    • Edited12. Is pregnant or breastfeeding or expecting to conceive within the projected duration of the study, starting with the pre-screening or screening visit through - 120 days after the last dose of study treatment.

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05603910
Lead sponsor
Aaron Wolfson
Responsible party
Aaron Wolfson (Professor of Radiation Oncology, University of Miami) — Sponsor-investigator
First posted
Nov 3, 2022
Start date
Apr 15, 2023
Primary completion
Apr 15, 2029 (estimated)
Completion
Apr 15, 2034 (estimated)
Last update
Nov 18, 2026

Study contacts

Aaron H Wolfson, MD, FACR
Contact
awolfson@med.miami.edu
954-698-3680
Aaron H Wolfson, MD, FACR
principal investigator · University of Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion